BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Beijing, China-based company plans to list on the Nasdaq under the symbol BGNE. BeiGene initially filed confidentially on August 28, 2015. Goldman Sachs, Morgan Stanley and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
Help employers find you! Check out all the jobs and post your resume.
